Other than surgery and medications, including opioids, there are few options for treating pain symptoms, which affect more than half of all patients with neurofibromatosis type 1.
Researchers recently reported on the results of a survey of patients with neurofibromatosis type 1 (NF1), a rare neurogenetic disorder causing benign and malignant tumors as well as pain that limits daily functioning.
NF1 affects men and women in equal numbers and affects all races and ethnic groups. It is estimated to occur in 1 in 2500 to 3000 births. NF1 is an autosomal dominant genetic condition; half of all cases arise de novo with a known family history of the disorder.
Other than surgery and medications, including opioids, there are few options for treating pain symptoms, which affect more than half of all patients. in addition, the spectrum of pain symptomatology and treatment, as well as the mechanisms underlying NF1-associated pain, have been understudied. Patients have treatment and quality-of-life challenges, as the pain is often not localized to a specific tumor.
Using the Washington University NF1 Patient Registry Initiative (NPRI) database, researchers conducted a survey of 255 adults, with the goal of identifying pain experience and symptoms, evaluating its impact on function, and determining the prevalence and complementary treatment modalities to reduce pain symptoms. Demographic and pain data were collected using a Qualtrics survey.
The survey found that all participants had at least 1 surgical procedure, with 55% reporting having at least 1 surgery within the last year and 17% being currently prescribed opioid medication.
There was a positive relationship (P <.001) between those prescribed pain medication and their pain severity and interference. Moreover, there was a significant relationship (P = .049) between the usage of complementary treatments and pain severity and interference.
The results show that individuals with NF1 report a higher incidence of pain severity and interference than observed in previous studies. The researchers wrote that the results highlight some salient points about NF1.
Women reported higher pain interference than men, although men reported higher pain severity than women. In addition, many of the patients who were experiencing pain had been dealing with these symptoms for more than 11 years and reported higher pain thresholds, indicating pain chronicity. Multiple regions of their body were affected with NF1 tumors.
The fact that tumor-related pain currently is primarily managed by surgery can be problematic, the authors wrote, given that NF1 tumors are located by nerve tissues or other vital structures and tumor regrowth following surgery is common. They noted that 43% of respondents reported complications from all surgical procedures, with a majority of those suffering permanent weakening of physical abilities following the surgery, permanently affecting their activities of daily living and their quality of life.
Seventeen percent were actively taking opioids to manage pain symptoms, comparable to the national average of 20%. Individuals taking opioids reported higher levels of pain severity and interference relative to those who were not prescribed these medications. Patient access to and knowledge of alternative treatments are needed, the researchers said.
Complementary treatments, such as yoga, massage therapy, and physical therapy, were shown to be effective with improvements in pain thresholds relative to non—evidence-based treatments, the authors wrote. These may improve pain management and reduce the risk of developing opioid dependence.
Reference
Buono FD, Grau LE, Sprong ME, Morford KL, Johnson KJ, Gutmann DH. Pain symptomology, functional impact, and treatment of people with neurofibromatosis type 1 [published online August 22, 2019]. J Pain Res. doi: 10.2147/JPR.S209540.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More